UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT

Size: px

Start display at page:

Download "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT"

Jesse Jacobs
5 years ago
Views:

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2015 (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of (Commission File Number) IRS Employer incorporation or organization) Identification No.) 655 Montgomery Street, Suite 900 San Francisco, CA (Address of Principal Executive Offices) (Zip Code) (408) (Registrant s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act Soliciting material pursuant to Rule 14a-12 under the Exchange Act Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

2 Item 1.01 Entry into a Material Definitive Agreement On January 13, 2014, Amarantus Bioscience Holdings, Inc. (the Company ) entered into a securities purchase agreement pursuant to which the Company agreed to issue 1, shares of its Series E Convertible Preferred Stock ( Series E Preferred Stock ) for gross proceeds of $1,000,000 bringing the total amount received by the Company from the sale of its Series E Preferred Stock to an aggregate of $6,000,000. On January 13, 2015, the Company filed a Certificate of Amendment to the Certificate of Designation to its Series E Convertible Preferred Stock to increase the number of Series E Preferred stock to 7,233 shares of Series E Preferred Stock. The sale of the shares of the Series E Preferred Stock were made upon the same terms and conditions of the Series E Preferred Stock transaction previously disclosed by the Company in its current reports on Form 8-K filed with the Securities and Exchange Commission on November 14, 2014 and December 24, Item 3.02 Unregistered Sales of Equity Securities. The information set forth in Item 1.01 is incorporated by reference herein. The issuance of the securities described above were completed in accordance with the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth in Item 1.01 is incorporated by reference herein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Certificate of Designation of Series E Preferred Stock filed January 13, 2014

3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: January 14, 2015 By: /s/ Gerald E. Commissiong Name: Gerald E. Commissiong Title: Chief Executive Officer

4 Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada (775) Website: Filed in the office of Document Number Amendment to Certificate of Designation Barbara K. Cegavske Filing Date and Time After Issuance of Class or Series Secretary of State 01/13/ :16 AM (PURSUANT TO NRS ) State of Nevada Entity Number E USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporations (Pursuant to NRS After issuance of Class or Series) 1. Name of corporation: Amarantus Bioscience Holdings, Inc. 2. Stockholder approval pursuant to statute has been obtained. 3. The class or series of stock being amended: Series E Convertible Preferred Stock 4. By a resolution adopted by the board of directors, the certificate of designation is being amended as follows or the new class or series is: The third Whereas clause of the Certificate of Designation of the Corporation for the Series E Convertible Preferred Stock shall be deleted in its entirety and replaced with the following. WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preference, restrictions and other matters relating to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Purchase Agreement, up to 7,223 shares of the preferred stock which the Corporation has the authority to issue, as follows: 5. Effective date of filing: (optional) 6. Signature: (required) /s/ Marc Faerber Signature of Officer Filing Fee: $ (must not be later than 90 days after the certificate is filed) IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected. This form must be accompanied by appropriate fess. Nevada Secretary of State NRS Amend Designation After Revised:

5 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF Pursuant to Section of the Nevada Revised Statutes SERIES E CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the Corporation ), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Corporation (the Board ): RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the Articles of Incorporation ): 1. The third Whereas clause of the Certificate of Designation of the Corporation for the Series E Convertible Preferred Stock shall be deleted in its entirety and replaced with the following: WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Purchase Agreement, up to 7,223 shares of the preferred stock which the Corporation has the authority to issue, as follows: 2. Section 2 of the Certificate of Designation of the Corporation for the Series E Convertible Preferred Stock shall be deleted in its entirety and replaced with the following: Section 2. Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series E 12% Convertible Preferred Stock (the Preferred Stock ) and the number of shares so designated shall be up to 7,223 (which shall not be subject to increase without the written consent of all of the holders of the Preferred Stock (each, a Holder and collectively, the Holders )). Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value equal to $1,000, subject to increase set forth in Section 3 below (the Stated Value ). IN WITNESS WHEREOF, the undersigned have duly signed this Certificate of Amendment to the Certificate of Designation of the Series E Convertible Preferred Stock as of this 13th day of January Amarantus BioScience Holdings, Inc. /s/ Marc Faerber By: Marc Faerber Title: Secretary and V.P. Finance

Live Ventures Incorporated (Exact name of registrant as specified in its charter)

Live Ventures Incorporated (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event